Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 129 clinical trials
Parrying the Pitfalls of PrEP: Project PEACH

occur as frequently as every 3 months, or as appropriate to clinical needs of HIV PrEP or STI PEP. The investigators will enroll men who may decide to start or stop PrEP, change from daily oral PrEP to

  • 0 views
  • 15 Jun, 2022
  • 1 location
Assessing the Feasibility and Preliminary Impact of a mHealth App on Reducing STI Risk in Black MSM PrEP Users

, "PCheck," on reducing the incidence of STIs, compared to routine care through the LSU-Crescent Care Sexual Health/PrEP Clinic.

Accepts healthy volunteers
  • 0 views
  • 16 Jun, 2022
  • 2 locations
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for the Treatment of In-Transit Melanoma, The Sofusa-2 Study

This phase Ib trial tests the safety, side effects, and best dose of STI-3031 given directly into the into the lymph nodes or the lymph vessels (intra-lymphatic) using the Sofusa DoseConnect

neutrophil count
thromboplastin
anticoagulant therapy
metastatic melanoma
cancer
  • 0 views
  • 30 Jun, 2022
  • 1 location
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US

The proposed research aims to assess the multiple forms and paths of stigma and substance use as they relate to pre-exposure prophylaxis (PrEP) use for HIV prevention. How stigma and an evolving public health landscape impact PrEP use among Black sexual minorit men who use substances is unknown. The current …

Accepts healthy volunteers
pre-exposure prophylaxis (prep)
HIV Vaccine
  • 0 views
  • 23 Mar, 2022
  • 1 location
Community-based Venues for Delivery of Healthcare Services: Proof of Concept Pilot

qualitative work, the package has been designed to include daily PrEP, family planning/contraceptives, and STI screening. Interested salon clients at intervention salons will elect which services to use. An

Accepts healthy volunteers
  • 0 views
  • 25 Mar, 2022
  • 1 location
Addressing Heavy Alcohol Use Consumption With Kudzu (A-HACK)

Drinking multiple alcoholic drinks on a single occasion (binge drinking), has many negative health risks but interventions to address this behavior remain limited. This double-blind, placebo-controlled randomized clinical trial will test whether kudzu, an herbal supplement, can reduce heavy alcohol use and alcohol-associated sexual behaviors among sexually-active, binge-drinking individuals at …

drug abuse
HIV Infection
antibody response
Accepts healthy volunteers
heavy drinking
  • 64 views
  • 04 Oct, 2022
  • 1 location
Appalachian Partnership to Reduce Disparities (Aim 2)

By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care

Accepts healthy volunteers
  • 0 views
  • 17 May, 2022
  • 1 location
Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention (PCORI PrEP)

The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prevent …

Accepts healthy volunteers
pre-exposure prophylaxis (prep)
HIV Vaccine
  • 0 views
  • 12 Oct, 2022
  • 3 locations
Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

>Bortezomib plus dexamethasone Vd: (Cohort 4) The secondary objectives of the study for each cohort are: To assess the preliminary anti-tumor activity by International Myeloma

carfilzomib
cancer
dexamethasone
bortezomib
okt3
  • 0 views
  • 24 Oct, 2022
  • 7 locations
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

refractory multiple myeloma
measurable disease
immunohistochemistry
bone marrow procedure
  • 0 views
  • 07 Oct, 2022
  • 1 location